维普期刊资源整合服务平台（V6.5）

125篇 您的检索式：作者名="Mathijssen"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	Danusertib, an au- rora kinase inhibitor显示文摘	Meulenbeld HJ Mathijssen RH Verweij J	2012	Expert Opin Investig Drugs2012，21，3：	1
2	Irinotecan pharmacokinetics pharmacodynamicsthe clinical relevance of prolonged exposure to SN-38显示文摘	Mathijssen RHJ Verweij J Loos WJ	2002	Br J Cancer2002，87，：	1
3	Irinotecan pharmacokinetics-pharmacodynamics:the clinical relevance of prolonged exposure to SN-38显示文摘	Mathijssen RH Verweij J Loos WJ	2002	Br J Cancer2002，87，2：	1
4	Variable recruitment of parallel elastic elements: Series-parallel elastic actuators (SPEA) with dephased mutilated gears显示文摘	Mathijssen G Lefeber D Vanderborght B	2015	IEEE/ASME Trans- actions on Mechatronics2015，20，2：	1
5	Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea显示文摘	Xie R Mathijssen RH Sparreboom A	2002	Clin Pharmacol Ther2002，72，3：	1
6	Structural heart defects associated with an increased nuchal translucency :9 years experience in a referral centre显示文摘	Clur S A Mathijssen I B Pajkrt E	2008	Prenat Diagn2008，28，4：	1
7	A CYlr3A4 phenotype-based dosing al- gorithra for individualized treatment of irinotecan 显示文摘	Vander JiM Mathijssen RH	2010	Clin Cancer Res2010，16，2：	1
8	Effects of St John's Wort on irinotecan metabolism 显示文摘	Mathijssen RHJ Verweij J De Bruijn P	2002	J Natl Cancer Inst2002，94，16：	1
9	Irinotecan phannacoki neties pharmaeodynamiesthe clinical relevance of prolonged 显示文摘	Mathijssen RHJ Verweij J Loos WJ	2002	Br J Cancer2002，87，：	1
10	Irinotecan pathway genotype analysis to predict pharmacokinetics 显示文摘	MATHIJSSEN RH MARSH S KARLSSON MO	2003	Clin Cancer Res2003，9，9：	1
11	Prediction of irinotecan pharmacokinetics by use of cytochreme 17450 3A4 phenotyping probes显示文摘	MATHIJSSEN RH JONG FA SCHAIK RH	2004	J Natl Cancer Inst2004，96，21：	1
12	Symptomatic Venous Thromhoemholism in Cancer Patients Treated with Chemotherapy: an Underestimated Phenomenon显示文摘	Otten H M Mathijssen J ten Cate H	2004	Arch Intern Med2004，164，2：	1
13	A gain-of-function TBX5 mutation is associated with atypical Holt Oram syndrome and paroxysmal atrial fibrillation显示文摘	Postma AV van de Meerakker JB Mathijssen IB	2008	Circ Res2008，102，11：	1
14	Symptomatic venous thromboembolism in cancer patients treated with chemotherapy:an underestimated phenomenon显示文摘	Otten HM Mathijssen J ten Cate H	2004	Arch Intern Med2004，164，2：	1
15	Clinical pharmacokinetics and metabolism of irinotecan( CPT-ll ) 显示文摘	MATHIJSSEN R H J van ALPHEN R J YERWEI J J et a1	2001	Clin Cancer Res2001，7，8：	1
16	Irinotecan pathway genotype analysis to predict pharmacokinetics 显示文摘	MATHIJSSEN R H MARSH S KARLSSON M O	2003	Clin Cancer Res2003，9，9：	1
17	The role of health technology assessment on pharmaceutical reimbursement in selected middle-in- come countries显示文摘	Oortwijn W Mathijssen J Banta D	2010	Health Policy2010，95，23：	1
18	Symptomatic venous throm- boembolism in cancer patientstreated with chemotherapy:an underesti- mated phenomenon显示文摘	Otten HM Mathijssen J ten Cate H	2004	Arch Intern Med2004，164，2：	1
19	Associations Between Environmental Characteristics and Active Commuting to School Among Children:A Cross-sectional Study显示文摘	Aarts M J Mathijssen J J P Oers J A M V	2013	International Society of Behavioral Medicine2013，20，4：	1
20	Moving towards dose individualization of tyrosine kinase inhibitors 显示文摘	KLUMPEN H J SAMER C F MATHIJSSEN R H	2011	Cancer Treat Rev2011，37，4：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示